Sheldon Sloan serves as Chief Medical Officer at Spyre Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Sheldon Sloan has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 9, 2026 involved receiving (via award) 140,000 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Jan 9, 2026 | SYRE | $0 | Award | 140,000 | $N/A | Discretionary |
Sheldon Sloan currently holds 140,000 shares of Spyre Therapeutics, Inc. (SYRE), valued at approximately $0. This represents their equity stake as Chief Medical Officer.
Based on SEC Form 4 filings, Sheldon Sloan has been a net neutral trader of SYRE stock. They have purchased $0 and sold $0 worth of shares.
Sheldon Sloan's most recent insider trade was on Jan 9, 2026, when they sold 140,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted